These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23461508)

  • 1. [Valproic acid serum through concentrations estimated from 12 hours post-dose concentrations in patients treated with Depakine® Crono].
    Lampón N; Tutor JC
    Farm Hosp; 2013; 37(1):79-80. PubMed ID: 23461508
    [No Abstract]   [Full Text] [Related]  

  • 2. [A retrospective study comparing two formulations of valproic acid].
    Gutiérrez-Gutiérrez G; Poza-Aldea JJ; Tellería-Elmezábal J; Martí-Massó JF
    Rev Neurol; 2006 Feb 1-15; 42(3):129-32. PubMed ID: 16475132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of slow-release preparations of sodium valproate.
    Yamatogi Y; Yoshinaga H; Oka E; Ohtahara S; Yamashita S; Furuno K; Gomita Y
    Psychiatry Clin Neurosci; 1995 Dec; 49(5-6):309-10. PubMed ID: 8726120
    [No Abstract]   [Full Text] [Related]  

  • 6. [Is treatment with a daily dose of Depakine Crono safe?].
    Martínez-Salio A; Porta-Etessam J; Berbel A; Manzanares-Secades C; Alvarez-Tejerina J; De La Peña P
    Rev Neurol; 2002 Jun 1-15; 34(11):1095-6. PubMed ID: 12134312
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy.
    Juárez-Olguín H; Lugo-Goytia G; Flores-Murrieta F; Ruiz-García M; Lares Asseff I; Flores Pérez J
    Rev Invest Clin; 2010; 62(6):516-23. PubMed ID: 21416779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

  • 9. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy.
    Jakovljevic MB; Jankovic SM; Jankovic SV; Todorovic N
    Epilepsy Res; 2008 Aug; 80(2-3):180-3. PubMed ID: 18495431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.
    Morath B; Green K; Zaradzki M; Heid J; Karck M; Hoppe-Tichy T
    Eur J Clin Pharmacol; 2018 May; 74(5):675-677. PubMed ID: 29362820
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum valproate levels with oral contraceptive use.
    Herzog AG; Farina EL; Blum AS
    Epilepsia; 2005 Jun; 46(6):970-1. PubMed ID: 15946343
    [No Abstract]   [Full Text] [Related]  

  • 15. Developmental and therapeutic pharmacology of antiepileptic drugs.
    Miura H
    Jpn J Psychiatry Neurol; 1993 Jun; 47(2):169-74. PubMed ID: 8271538
    [No Abstract]   [Full Text] [Related]  

  • 16. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
    Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.